Roche’s Muscle-Wasting Treatment Shows Positive Results in Late-Stage Trial
The data showed reduced difficulties in standing, walking and running that were statistically significant, the company said.
Healio4d
FDA grants fast-track designation to myotonic dystrophy type 1 treatment
The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals with myotonic ...
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Initiation of Phase 1b study using SGT-212 for the treatment of patients with Friedreich's Ataxia expected in 2H25. Click ...
Solid Biosciences gets FDA Fast Track for FA gene therapy
CHARLESTOWN, Mass. - Solid Biosciences Inc. (NASDAQ:SLDB), a $130.65 million market cap biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) ...
Dyne Gets FDA Fast-Track Status for Neuromuscular Product Candidate
Dyne Therapeutics received fast-track designation from the Food and Drug Administration for a treatment of myotonic dystrophy type 1, a neuromuscular disease.
The New York Times23d
Arsenal’s Ethan Nwaneri suffers muscular injury, says Mikel Arteta: ‘We’ve lost him’
Arsenal goalscorer Ethan Nwaneri was substituted at half-time against Brighton & Hove Albion because of a muscular injury, Mikel Arteta has said. The 17-year-old opened the scoring for Arsenal in ...
Medical Xpress25d
New insights into protein roles in Duchenne muscular dystrophy
offering new pathways for understanding and treating Duchenne Muscular Dystrophy (DMD). DMD, a severe genetic disorder that causes muscle weakness and shortens lifespans, arises from mutations in ...
Science Daily27d
New study uncovers key insights into protein interactions in Duchenne muscular dystrophy, paving way for more targeted therapies
offering new pathways for understanding and treating Duchenne Muscular Dystrophy (DMD). A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to ...